Table 1

Clinical and immunological features of human immunodeficiency virus 1 (HIV-1) infected patients in relation to treatment regimen

Patient No, sex, age (y)Anti-HIV regimen and durationCurrent infectionsCurrent antibioticsOther serious diseasesBlood CD4+ T cells (109/l)Plasma HIV RNA (copies/ml)Duodenal IgA (No/mucosal unit)
ND, not determined; TMP, trimethoprim; SMX, sulphamethoxazole; NA, nucleoside analogues; HAART, highly active antiretroviral therapy; CMV, cytomegalovirus; MAC, Mycobacterium avium intracellulare complex; Tbc, tuberculosis; PCP, Pneumocystis carinii pneumonia; Pc, penicillin; UTI, urinary tract infection.
1. M, 44NoneHerpes oesophagitis, oral candidiasisFluconazoleNon-Hodgkin’s lymphoma later0.01ND243.7
2. M, 38NoneCryptosporidiosisNone0.02ND305.4
3. M, 31NoneCandida oesophagitis, cryptosporidiosisFluconazole0.03ND145.5
4. M, 39NoneCandida oesophagitisFluconazole, TMP/SMXEthanol abuser0.008ND230
5. M, 26NoneOral candidiasis, toxoplasmosisFluconazole, TMP/SMXHepatitis C, cerebral lesions0.009ND152.7
6. M, 38NoneCandida oesophagitis, pneumonia, genital herpesClindamycin, tobramycinNon-Hodgkin’s lymphoma0.012ND131
7. M, 44NoneHeroin abuser, hepatitis C0.132130 000209.1
8. M, 49NoneOral candidiasisTMP/SMX, NystatinWasting0.0557 00095.2
9. M, 341 NA, 35 moSystemic candida infection, UTI, MAC and PCP infectionTMP/SMX, ethambutol, clarithromycin, ketoconazoleCerebral haematoma0.001ND121
10. F, 401 NA, 6 moCandida oesophagitisFluconazole, TMP/SMX, ethambutol, azithromycinHeroin abuser0.01ND276.1
11. M, 341 NA, 10 moHeroin abuser, hepatitis C, wasting0.22ND224.8
12. F, 261 NA, 8 moMACNystatin, acyclovir, ketoconazole0.02ND264.5
13. M, 382 NA, 5–7 daysCandida oesophagitis, MACTMP/SMX, fluconazole, doxycyclinHeroin abuser0.01270 000177.3
14. F, 382 NA, 7 weeksTMP/SMXHeroin abuser, wasting, hepatitis B+C, AIDS dementia0.114ND101.6
15. M, 482 NA, 8 moPleuritis, herpes oesophagitisTMP/SMXStenosis valvula aortae0.1321400105.1
16. M, 282 NA, 14 daysPCP infection, oral candidiasisTMP/SMX, fluconazoleOesophageal ulcers0.002ND243.2
17. M, 292 NA, 18 moOral candidiasis, toxoplasmosisTMP/SMXWasting, cerebral lesions0.015ND108.8
18. M, 422 NA, 3 moTbc lymphadenitisTMP/SMX, fluconazole, ethambutol0.02ND108.9
19. M, 412 NA, 42 moSystemic CMV infectionAmphotericin B, ketoconazoleGastritis0.072ND139.5
20. M, 372 NA, 8 moCandida oesophagitisTMP/SMXKaposi sarcoma0.018ND268.9
21. F, 39HAART, 8 daysSepticaemia, pneumonia, oral candidiasisPc, fluconazoleHeroin abuser, hepatitis B+C0.24ND25.5
22. M, 39HAART, 5 moPneumonia, candida oesophagitisTMP/SMX, fluconazoleHeroin abuser, hepatitis B+C0.0116 000107.1
23. M, 40HAART, 13 moMACClarithromycin, ethambutol, ciprofloxacinPulmonary bacillar angiomatosis0.19<400101.7
24. F, 33HAART, 15 moMAC, sinusitis, pelvic abscessCiprofloxacin, ethambutol, rifabutin0.14380 00088.9
25. M, 45HAART, 14 moSystemic CMV infectionClarithromycin, ethambutolGranulomatous hepatitis (side effect?)0.2542 000111.9
26. F, 32HAART, 6 daysOral candidiasisFluconazoleHeroin abuser, wasting0.054110 000117.6
27. M, 44HAART, 10 moCandida oesophagitis, gastritisTMP/SMXWasting0.05>750 000131.9
28. M, 43HAART, 3 moCandida oesophagitis, MAC, genital herpesEthambutol, rifampin, clarithromycin, ciprofloxacin, acyclovir0.006ND115.9
29. M, 29HAART, 2 moCandida oesophagitisTMP/SMX, fluconazoleWasting0.009ND112.2
30. M, 52HAART, 3 moOral candidiasis, candida oesophagitis, MACTMP/SMX, fluconazole0.024<40032.4
31. M, 39HAART, 8 daysCandida oesophagitisKetoconazole0.112190 000129.7